– Interview with Robert Langer, Ph.D., Institute Professor, Chemical and Biomedical Engineering, MIT

PodcastsResourcesBrain cancerCancersDrug deliveryGenetic engineeringGenetic Engineering and BiotechnologyMedicine, Diagnosis, and TherapeuticsNanoparticlesNanotechnologyPharmacologyRegenerative engineeringSystemic conditionsTechnology and Computational BiologyTissue engineering
Previous articleUpdated Exubera Label Warning of Lung Cancer Cases Triggers Nektar to Quit Search for Partner
Next articleMerck & Co. In-Licenses Cancer Targets from Celera to Develop RNAi Drugs